Study of synergisms of anticancer drug ellipticine and alfa5 beta1 integrin in brain cancer treatment

Provider

Ministry of Education, Youth and Sports

Programme

KONTAKT

Call for proposals

—

Main participants

—

Contest type

M2 - International cooperation

Contract ID

6094/2009-32

Project name in Czech

Studium synergismu protinádorového léčiva ellipticinu a alfa5 beta1 integrinu v léčbě nádorů mozku

Annotation in Czech

Cílem projektu je poznání, zda je možné vyvolat synergismus ůčinku protinádorového chemotherapeutika ellipticinu a inhibitory alfa5 beta1 integrinu, konkrétně v léčbě nádorů mozku.

R&D category

ZV - Basic research

CEP classification - main branch

CE - Biochemistry

CEP - secondary branch

—

CEP - another secondary branch

—

OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)

10608 - Biochemistry and molecular biology<br>10609 - Biochemical research methods

Provider evaluation

U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)

Project results evaluation

Results found during solving the MEB 020837 project explain synergic effects of ellipticine and a5b1 integrin in treatment of brain cancer. Cytotoxicity of ellipticine to human glioblastoma cells is explained by formation of DNA adducts.e ?5?1 integrin antagonists reduce ellipticine-induced premature senescence and facilitate apoptosis in these cells.

Realization period - beginning

Jan 1, 2008

Realization period - end

Dec 31, 2009

Project status

U - Finished project

Latest support payment

Apr 1, 2009

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data delivery code

CEP10-MSM-ME-U/01:1

Data delivery date

Jun 30, 2010

Total approved costs

29 thou. CZK

Public financial support

29 thou. CZK

Other public sources

0 thou. CZK

Non public and foreign sources

0 thou. CZK